0.21
0.21 (0%)
As of Feb 14, 2025
Lyra Therapeutics, Inc. [LYRA]
Source:
Company Overview
Lyra Therapeutics, Inc is a clinical-stage biotechnology company focused on the development and commercialization of innovative, anti-inflammatory therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. Our primary product candidate, LYR-210, is a bioabsorbable nasal insert designed to be administered in a simple, in-office procedure and intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration.
| Country | United States |
| Headquarters | watertown, massachusetts |
| Phone Number | 617-373-4600 |
| Industry | manufacturing |
| CEO | Maria Palasis |
| Website | www.clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $1.5 |
| Operating Profit | $-96.3 |
| Net Income | $-93.4 |
| Net Cash | $18.8 |
Profit Ratios
| Gross Margin | $1.5 |
| Operating Margin | -6,280.8 |
| Profit as % of Revenues | -1.6% |
| Profit as % of Assets | -89.4% |
| Profit as % of Stockholder Equity | -805.9% |
Management Effectiveness
| Return on Equity | -805.9% |
| Return on Assets | -140.8% |
| Turnover Ratio | 1.5% |
| EBITA | $-96.3 |
Balance Sheet and Cash Flow Measures
| Total Assets | $66.3 |
| Total Liabilities | $54.8 |
| Operating Cash Flow | $-70 |
| Investing Cash Flow | $80.3 |
| Financing Cash Flow | $8.5 |
